From 1990 to 2017, there were increases in the global prevalence, incidence, and burden of suffering related to psoriasis.
There are sex- and gender-specific differences related to clinical characteristics and quality-of-life measures in patients with psoriasis.
Early markers of cardiovascular and metabolic disease were elevated in adolescents with psoriasis, despite early disease.
The prenatal period is of greatest importance in tobacco’s effect on risk for pediatric psoriasis, suggesting that smoking may play a causal role in psoriasis pathogenesis, a novel study finds.
Surprising dietary findings show Japanese patients with psoriasis had higher BMI, lower intake of meat, and higher intake of seafood, sugar/sweeteners, vitamin D and vitamin B12, challenging long-held nutritional beliefs.
Overall cancer mortality and mortality for liver, esophageal, pancreatic cancer up with severe psoriasis.
Patients and providers agreed that Skindex instruments are important complements to patient global assessments for determining disease burden and severity in clinical practice.
Use of cyclosporine, infliximab, and anti-IL17 agents may be associated with increased risk of symptomatic urinary tract infection in women with psoriasis.
A clinical guideline for the use of phototherapy for the care and management of adult patients with psoriasis developed by the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) has been published.
Findings indicated by perivascular fat attenuation index, as measured by coronary CT angiography.
Type, rather than number, of comorbidities, has a greater effect on the quality of life of patients with psoriatic arthritis, according to recent research.
41, 39.5 percent use alternative, complementary therapies; higher use seen with severe psoriasis.
High waist circumference, regardless of overall body mass index, tied to higher risk.
Time to onset found to be 2 to 3 months for anxiety disorders and other conditions.
Addition of apremilast to a regimen of topical corticosteroids was safe and effective in patients with moderate plaque-type psoriasis.
A fixed-dose combination lotion comprised of halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) is more effective for treating moderate-to-severe plaque psoriasis than either component alone.
Researchers completed 2 post hoc analyses of large, double-blind trials examining the efficacy of HP/TAZ combination therapy for clinically meaningful outcomes.
The extracutaneous manifestations of psoriasis and guidance on use of biologic treatment for management of psoriasis are discussed in 2 new guidelines.
In patients with hypertension, psoriasis linked to increased risk for cardiovascular procedures, surgeries.
DLQI-R allows more patients to achieve threshold for becoming candidates for biologic treatment.